FDA Clearance of IND for Ketamir-2, Novel Oral NMDA Receptor Antagonist for Neuropathic Pain
July 30th 2025The FDA has cleared the IND application for MIRA Pharmaceuticals' Ketamir-2, a promising oral treatment for neuropathic pain, which has shown superior efficacy and safety in preclinical studies.
The Impact of Valproic Acid on Neonatal Outcomes
Research reveals significant risks of neonatal complications linked to in utero valproic acid exposure, emphasizing the need for careful management during pregnancy.
Valproic Acid During Pregnancy and After Delivery: A Narrative Review
Valproic acid poses significant risks during pregnancy, including congenital malformations and neurodevelopmental disorders, necessitating careful treatment planning.